Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
复制标题
DOI：
10.1111/bjh.14870
复制
发表时间：
2017-11
影响因子：
6.5
通讯作者：
Wang M
中科院分区：
文献类型：
--
作者：
Rule S;Dreyling M;Goy A;Hess G;Auer R;Kahl B;Cavazos N;Liu B;Yang S;Clow F;Goldberg JD;Beaupre D;Vermeulen J;Wildgust M;Wang M
ibrutinib高度活跃，在攻击性的B细胞淋巴瘤（MCL）中，我们从三个Ibrutinib研究中汇总了数据，以探索基线患者特征对接送的患者的影响。 （DOR），无进展生存(PFS) and overall survival (OS) were 18.6, 12.8 and 25.0 months, respectively. Univariate analyses showed patients with one versus > one prior line of therapy had longer OS. Multivariate analyses identified that one prior line of therapy affected PFS; Eastern Cooperative Oncology Group (ECOG) performance status, simplified MCL international prognostic index (sMIPI) score, bulky disease, and blastoid histology affected OS and PFS的患者与非乳化组织学相似，但较低的ORR，DOR，PFS和OS的患者在患有更好的SMIPI的患者中，ECOG性能状态为0-1，非卵子疾病和非乳酸群体的患者增加。在治疗后，依鲁替尼的治疗失败与疾病的自然生物学演化有关。
Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18.6, 12.8 and 25.0 months, respectively. Univariate analyses showed patients with one versus >one prior line of therapy had longer OS. Multivariate analyses identified that one prior line of therapy affected PFS; Eastern Cooperative Oncology Group (ECOG) performance status, simplified MCL international prognostic index (sMIPI) score, bulky disease, and blastoid histology affected OS and PFS. Patients with blastoid versus non-blastoid histology had similar time to best response, but lower ORR, DOR, PFS and OS. OS and PFS were longer in patients with better sMIPI, patients with ECOG performance status 0–1, non-bulky disease and non-blastoid histology. Additionally, the proportion of patients with poor prognostic factors increased with increasing lines of therapy. Together, results suggest that patient outcomes following treatment failure with ibrutinib are related to the natural biological evolution of the disease.
登录
查看更多内容
影响因子：
20.3
作者：
Flinn, Ian W.;van der Jagt, Richard;Burke, John M.
通讯作者：
Burke, John M.
影响因子：
20.3
作者：
Ponader, Sabine;Chen, Shih-Shih;Burger, Jan A.
通讯作者：
Burger, Jan A.
影响因子：
50.5
作者：
Cheah, C. Y.;Chihara, D.;Wang, M. L.
通讯作者：
Wang, M. L.
影响因子：
20.3
作者：
Martin, Peter;Maddocks, Kami;Blum, Kristie A.
通讯作者：
Blum, Kristie A.
影响因子：
20.3
作者：
Herman, Sarah E. M.;Gordon, Amber L.;Byrd, John C.
通讯作者：
Byrd, John C.